What is the global market size of Myocardial Infarction (MI) Therapeutics Market?

Myocardial Infarction (MI) Therapeutics Market was valued to be US$ 1.91 billion in 2021, and it is expected to reach US$ 2.65 billion by 2028 at a CAGR of 4.82% over the forecast period 2022 - 2028.

Global Myocardial Infarction (MI) Therapeutics Market Size, Share, Growth Analysis, By Treatment/Drug Type(Antiplatelet Agents, Glycoprotein IIb/IIIa Inhibitors), By Route of Administration(Oral, Injectable), By Distribution Channel(Offline drug stores (Retail Pharmacies, Hospital Pharmacies)) - Industry Forecast 2024-2031

Report ID: SQSG35I2029 | Region: Global | Published Date: February, 2024
Pages: 257 | Tables: 95 | Figures: 70

Global Myocardial Infarction (MI) Therapeutics Market News

In May 2021, Recardio Inc., a clinical-stage life science firm specializing in regenerative therapeutics for cardiovascular disorders, finished its Phase 2 randomized, double-blind, placebo-controlled, safety, and efficacy study of dutogliptin combined with filgrastim in early recovery post-myocardial infarction.
In May 2020, Eli Lilly and Company, Boehringer Ingelheim, and the Duke Clinical Research Institute (DCRI) collaborated on academic research for the new study of EMPACT-MI (EMPAgliflozin for the prevention of Chronic heart failure and morTality after an acute Myocardial Infarction).

Global Myocardial Infarction (MI) Therapeutics Market Report Snapshots

License Type Top market research company in USA

File Type

$5,300

BUY NOW GET FREE SAMPLE

Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Myocardial Infarction (MI) Therapeutics Market was valued to be US$ 1.91 billion in 2019, and it is expected to reach US$ 2.65 billion by 2031 at a CAGR of 4.82% over the forecast period 2022 - 2028.

Due to the presence of numerous established as well as new businesses in this sector, the market for myocardial infarction treatments is extremely fragmented and established. It is expected that new competitors will attempt to enter this market in the near future due to the rising incidence and prevalence of acute myocardial infarction and other cardiovascular disorders. 'Bayer HealthCare LLC (Germany)', 'Daiichi Sankyo, Inc. (Japan)', 'Eli Lilly and Company (US)', 'Janssen Biotech, Inc. (US)', 'Merck & Co. Inc. (US)', 'Novartis International AG (Switzerland)', 'Sanofi (France)', 'AstraZeneca (UK)', 'Pfizer (US)', 'Amgen, Inc (US)', 'GlaxoSmithKline PLC (UK)', 'Regeneron Pharmaceuticals Inc. (US)', 'Bristol-Myers Squibb Company (US)', 'Alnylam Pharmaceuticals Inc. (US)'

The global myocardial infarction market is projected to increase as heart attacks become more common. Apart from this, the two main drivers anticipated to propel the growth of the global market for myocardial infarction therapies are the rising incidence of coronary artery disease and changes in lifestyle. Over the forecast period, rising blood pressure, obesity, and smoking rates, among other factors, are predicted to propel the global market for myocardial infarction treatments.

The delivery of medications and imaging probes using nanoparticle technology offers new approaches for the treatment of cardiovascular disease (CVD). With significant efforts being made to address therapy possibilities for myocardial infarction (MI), advancements in the production of nanoparticles, their design characteristics, and functional diversity have permitted its direct implementation in preclinical CVD research. It is possible to create nanocarrier systems with efficient cell-, tissue-, or disease-specific and targeted actions through the rational design of nanoparticles, resolving problems with low bioactive factor delivery efficiency, difficulty crossing biological barriers, ineffective bioimaging, and unfavorable off-target effects that would otherwise impede the advancement of cardiovascular medicine. In particular, the control of inflammation and fibrogenesis, the encouragement of angiogenesis, and accelerated tissue regeneration are driving efforts to create more effective therapeutic and diagnostic solutions for clinical issues faced by MI treatment.

Based on the region, the North American region currently dominates the global myocardial infarction (MI) therapeutics market. This is due to the rising prevalence of cardiovascular disorders and the growing senior population, that the market for myocardial infarction treatment is expanding admirably in this region. The increased frequency of obesity and chronic disorders like diabetes, hypertension, and chronic kidney disease are further reasons driving this market's expansion. Additionally, unhealthy lifestyle habits, excessive alcohol consumption, and drug use—including amphetamine and cocaine use—among the populace are significant risk factors for myocardial infarction. As a result, the market for myocardial infarction treatment and management products is expected to grow in the coming years. According to estimates, the global market for myocardial infarction treatments has the potential to be lucrative and to grow due to the rising popularity of efficient and secure treatment protocols. The market for myocardial infarction treatments may develop as a result of anticipated technology advancements that will create a plethora of chances for detecting specific blockages, monitoring cellular response, and determining hereditary predisposition.

Feedback From Our Clients

"We have purchased recently a report from SkyQuest Technology, and we are happy to inform you that this report was so useful and practical for our team. Skyquest Team was very active and our queries were followed up completely.It was amazing. "

- Mr. Ali Zali, Commercial Director, ICIIC Iran.

Global Myocardial Infarction (MI) Therapeutics Market News

Global Myocardial Infarction (MI) Therapeutics Market Report Snapshots

Want to customize this report?

FAQs

What is the global market size of Myocardial Infarction (MI) Therapeutics Market?

Who are the key vendors in the Global Myocardial Infarction (MI) Therapeutics Market?

What is the key driver of Global Myocardial Infarction (MI) Therapeutics Market?

What is the key market trend for Global Myocardial Infarction (MI) Therapeutics Market?

Which region accounted for the largest share in Global Myocardial Infarction (MI) Therapeutics Market?

Request Free Customization

Related Reports

Feedback From Our Clients

$5,300